Lead Product(s) : Tisolagiline
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Scilex Reports KDS2010 Ph 2 Trial for Alzheimer’s Disease with U.S. Patient Cohort in 2025
Details : KDS2010 (Tisolagiline) is a potent, selective, and reversible Monoamine oxidase B (MAO-B) inhibitor being invesigated as a novel oral tablet small molecule agent for treating Alzheimer’s Disease.
Product Name : KDS2010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Tisolagiline
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tisolagiline
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Scilex Bio Reports Positive Phase 1 Results for KDS2010, a Novel MAO-B Inhibitor
Details : KDS2010 (Tisolagiline) is a potent, selective, and reversible Monoamine oxidase B (MAO-B) inhibitor being invesigated as a novel oral tablet small molecule agent for treating obesity.
Product Name : KDS2010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Tisolagiline
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tisolagiline
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Scilex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NeuroBiogen, Scilex Partner for Global KDS2010 Licensing in Phase 2 Diseases
Details :
Product Name : KDS2010
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : Tisolagiline
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Scilex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Tisolagiline
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : IPMC
Deal Size : Undisclosed
Deal Type : Partnership
Scilex, IPMC, Bio Open Consortium Partner on Phase 2 Obesity Drug Development
Details : The joint venture will have global development and commercialization rights for a Phase 2, best-in-class novel oral tablet, KDS2010, for obesity and neurodegenerative diseases including Alzheimer.
Product Name : KDS2010
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : Tisolagiline
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : IPMC
Deal Size : Undisclosed
Deal Type : Partnership